Galecto Inc (GLTO)

$0.55

+0.03

(+5.8%)

Market is closed - opens 7 PM, 15 Jul 2024

Insights on Galecto Inc

  • Vs NVO

    In the last 1 year, Novo Nordisk A/s has given 80.7% return, outperforming this stock by 160.5%

  • Vs NVO

    In the last 3 years, Novo Nordisk A/s has given 222.8% return, outperforming this stock by 311.4%

Performance

  • $0.52
    $0.56
    $0.55
    downward going graph

    4.64%

    Downside

    Day's Volatility :6.34%

    Upside

    1.79%

    downward going graph
  • $0.46
    $3.70
    $0.55
    downward going graph

    16.36%

    Downside

    52 Weeks Volatility :87.57%

    Upside

    85.14%

    downward going graph

Returns

PeriodGalecto IncIndex (Russel 2000)
3 Months
-24.36%
0.0%
6 Months
-25.13%
0.0%
1 Year
-79.8%
0.0%
3 Years
-88.6%
-22.5%

Highlights

Market Capitalization
13.6M
Book Value
$1.04
Earnings Per Share (EPS)
-1.13
Wall Street Target Price
5.5
Profit Margin
0.0%
Operating Margin TTM
0.0%
Return On Assets TTM
-36.95%
Return On Equity TTM
-78.56%
Revenue TTM
0.0
Revenue Per Share TTM
0.0
Quarterly Revenue Growth YOY
0.0%
Gross Profit TTM
0.0
EBITDA
-28.5M
Diluted Eps TTM
-1.13
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-1.06
EPS Estimate Next Year
-1.14
EPS Estimate Current Quarter
-0.41
EPS Estimate Next Quarter
-0.39

Analyst Recommendation

Buy
    75%Buy
    25%Hold
    0
    0%Sell
Based on 8 Wall street analysts offering stock ratings for Galecto Inc(by analysts ranked 0 to 5 stars)
Based on 8 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
6
6
6
Hold
2
2
3
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 900.0%

Current $0.55
Target $5.50

Technicals Summary

Sell

Neutral

Buy

Galecto Inc is currently in a neutral trading position according to technical analysis indicators.

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Galecto Inc
Galecto Inc
-2.83%
-25.13%
-79.8%
-88.6%
-96.57%
Moderna, Inc.
Moderna, Inc.
-16.86%
15.92%
-2.46%
-48.68%
764.93%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
5.12%
15.76%
50.37%
88.19%
269.25%
Novo Nordisk A/s
Novo Nordisk A/s
-2.42%
30.45%
80.67%
222.84%
488.09%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
3.43%
13.55%
42.21%
148.12%
179.95%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Galecto Inc
Galecto Inc
NA
NA
NA
-1.06
-0.79
-0.37
NA
1.04
Moderna, Inc.
Moderna, Inc.
24.73
NA
0.0
-7.18
-0.38
-0.16
NA
33.47
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
31.64
31.64
1.46
44.29
0.15
0.08
NA
250.15
Novo Nordisk A/s
Novo Nordisk A/s
49.22
49.22
2.36
3.47
1.0
0.25
0.01
22.18
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
31.94
31.94
0.53
17.02
0.24
0.13
NA
71.8
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Galecto Inc
Galecto Inc
Buy
$13.6M
-96.57%
NA
0.0%
Moderna, Inc.
Moderna, Inc.
Buy
$47.1B
764.93%
24.73
-115.82%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$118.0B
269.25%
31.64
29.45%
Novo Nordisk A/s
Novo Nordisk A/s
Buy
$635.7B
488.09%
49.22
36.55%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$126.9B
179.95%
31.94
39.46%

Institutional Holdings

  • Novo A/S

    9.21%
  • Renaissance Technologies Corp

    2.14%
  • Vanguard Group Inc

    0.82%
  • Geode Capital Management, LLC

    0.77%
  • Bridgeway Capital Management, LLC

    0.27%
  • BlackRock Inc

    0.19%

Company Information

galecto biotech is a newly founded company, focused on developing novel drugs for the treatment of fibrosis, inflammation and other serious human diseases. the company’s products target galectins, a group of proteins that play important roles in many disorders. galecto biotech’s high potency galectin modulators may open new treatment possibilities for many patients. the company, which is located in lund, sweden, is led by top-level scientists and biotech executives.

Organization
Galecto Inc
Employees
13
CEO
Dr. Hans T. Schambye M.D., Ph.D.
Industry
Health Technology

FAQs